GLP-1-based incretin therapy is associated with lower incident Alzheimer's disease and cardiorenal events in adults with documented neuropsychiatric, cognitive, or sensory risk.
Summary withdrawn
TitrateLab removes an AI-written study summary when it states findings we cannot trace to the study's own record, or when the study falls outside the compounds we track. Read the original record through the link above.
